Sell Rating on Fulcrum Therapeutics Due to Uncertain Prospects and Financial Concerns

Fulcrum Therapeutics (FULC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on the stock and has a $2.00 price target.

Tazeen Ahmad’s rating is based on several concerns regarding Fulcrum Therapeutics’ current and future prospects. The company is in the early stages of its sickle cell disease program, with data from the phase 1b trial expected only by mid-2025. This delay, coupled with the need for further FDA discussions, contributes to uncertainty about the program’s success and potential market expansion.
Additionally, Fulcrum’s financial performance and pipeline developments raise caution. The recent failure of their losmapimod study and the lack of detailed information on their preclinical programs, such as the Diamond-Blackfan anemia initiative, add to the risk profile. These factors, combined with a conservative valuation model that reflects limited near-term revenue potential, underpin Ahmad’s Sell rating for the stock.